Identifying patients with high risk of low response to statin therapy is important for optimization of lipid-lowering therapy. Cholesterol 7α-hydroxylase, a rate-limiting enzyme encoded by cytochrome P450 7A1 (CYP7A1
) gene, is considered to be associated with statin efficacy. This study aimed to investigate the association between a novel CYP7A1
single nucleotide polymorphism rs3824260 and statin treatment response for hypercholesteremic patients in Chinese Han population.
A total of 336 subjects were prescribed with simvastatin
for 12 weeks after enrollment. Plasma lipid parameters were measured at enrollment and after 12-week simvastatin
treatment separately. Subjects were classified into high- and low-response groups depending on their total cholesterol, low-density lipoprotein cholesterol (LDL-C) and TG changes and increase or reduction groups according to their high-density lipoprotein
cholesterol (HDL-C) levels changing after simvastatin
treatment. The CYP7A1
rs3824260 was genotyped from blood samples with a SNaPshot assay.
At baseline, the LDL-C level and TG level were significantly higher in the AA genotype, while the HDL-C level was significantly higher in the GG genotype of CYP7A1
rs3824260. Patients carrying AA genotype are at an increased risk of low response for LDL-C reduction (odds ratio = 2.295, 95% confidence interval = 1.164–4.524, P
= 0.016). Furthermore, the GG genotype of rs3824260 was significantly associated with a high risk of HDL-C reduction response after simvastatin
therapy (odds ratio = 2.240, 95% confidence interval = 1.137–4.413, P
gene polymorphism rs3824260 is related to inappropriate response of simvastatin
treatment for hypercholesterolemia
patients in Chinese Han population.